Siren Biotechnology develops novel cancer treatments by integrating AAV gene therapy with cytokine immunotherapy into a single therapeutic modality. This approach aims to create a universal immuno-gene therapy effective against various solid tumors. The company is initially focusing on brain cancer as a key therapeutic area to establish this new treatment standard.
Funding
$25.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MFounders
Product
Problem
Existing treatments for solid tumors, particularly brain cancer, face challenges in delivery, efficacy, and toxicity, leading to limited success in improving patient outcomes. The aggressive nature and complex microenvironment of solid tumors often hinder therapeutic interventions.
Solution
Siren Biotechnology is developing a universal AAV immuno-gene therapy platform that combines adeno-associated virus (AAV) gene therapy with cytokine immunotherapy to treat various solid tumors. This approach aims to enhance treatment efficacy by leveraging the targeted delivery capabilities of AAV vectors and the immune-stimulating effects of cytokine immunotherapy. By addressing the limitations of conventional cancer therapies, Siren Biotechnology seeks to establish AAV immuno-gene therapy as a foundational treatment modality for a range of cancers. Their lead asset, SRN-101, is being developed for high-grade gliomas and has received Orphan Drug and Rare Pediatric Disease Designations from the FDA.
Target Audience
The primary target audience includes patients with solid tumors, particularly those with brain cancer, and the healthcare providers who treat them, including oncologists and neuro-oncologists.
Features
- Combines AAV gene therapy with cytokine immunotherapy for a synergistic effect.
- Utilizes AAV vectors for targeted delivery of therapeutic genes to tumor cells.
- Employs cytokine immunotherapy to stimulate the patient's immune system to fight cancer.
- Focuses on solid tumors, including brain, eye, liver, skin, lung, bladder, breast, kidney, pancreatic, Merkel, ovarian, and prostate cancers.
- Lead asset SRN-101 targets high-grade gliomas.